Travere Therapeutics Inc (TVTX): Next-Year EPS Estimate 9888.53%
As of 2026-08-25, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 9888.53%. Featured in 2 EPS revision reports, most recently on 2026-04-15.
On 2026-08-06, analyst consensus for TVTX's next-year EPS growth shifted from 4159.03% to 9888.53% — a positive change of 5729.50 percentage points. The revised estimate has been sustained across 17 subsequent trading sessions. Current-year growth is projected at 88.86%.
What's Driving This
Analysts’ dramatic upward revision of TVTX’s next-year EPS growth estimate—from 4159% to 9888%—is the primary structural driver behind the stock’s rise. The revision was plausibly triggered by the Q2 2026 earnings call, which highlighted record FILSPARI demand. Investor conference participation and broader biotech sector attention have helped sustain momentum beyond that initial upgrade.
Generated 2026-08-25 from news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 9888.53%
- EPS growth this year
- 88.86%
- EPS next quarter (est)
- $0.02
- Last price
- $67.01
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 9888.53% | 88.86% | $0.02 | $67.01 |
| 2026-08-24 | 9888.53% | 88.86% | $0.02 | $65.22 |
| 2026-08-23 | 9888.53% | 88.86% | $0.02 | $65.71 |
| 2026-08-21 | 9888.53% | 88.86% | $0.02 | $65.71 |
| 2026-08-20 | 9888.53% | 88.86% | $0.02 | $64.46 |
| 2026-08-19 | 9888.53% | 88.86% | $0.02 | $65.96 |
| 2026-08-18 | 9888.53% | 88.86% | $0.02 | $63.90 |
| 2026-08-17 | 9888.53% | 88.86% | $0.02 | $63.53 |
| 2026-08-16 | 9888.53% | 88.86% | $0.02 | $62.14 |
| 2026-08-14 | 9888.53% | 88.86% | $0.02 | $62.14 |
| 2026-08-13 | 9888.53% | 88.86% | $0.02 | $61.43 |
| 2026-08-12 | 9888.53% | 88.86% | $0.02 | $62.16 |
| 2026-08-11 | 9888.53% | 88.86% | $0.02 | $60.21 |
| 2026-08-10 | 9888.53% | 88.86% | $0.02 | $60.89 |
| 2026-08-09 | 9888.53% | 88.86% | $0.02 | $61.32 |
| 2026-08-07 | 9888.53% | 88.86% | $0.02 | $61.32 |
| 2026-08-06 | 9888.53% | 88.86% | $0.02 | $62.45 |
| 2026-08-05 | 4159.03% | 74.48% | $0.01 | $62.76 |
| 2026-08-04 | 1570.75% | 44.88% | -$0.18 | $56.02 |
| 2026-08-03 | 1570.75% | 44.88% | -$0.13 | $54.98 |
| 2026-08-02 | 1570.75% | 44.88% | -$0.13 | $55.89 |
| 2026-07-31 | 1570.75% | 44.88% | -$0.13 | $55.89 |
| 2026-07-30 | 1570.75% | 44.88% | -$0.13 | $57.28 |
| 2026-07-29 | 7084.07% | 88.09% | -$0.11 | $55.56 |
| 2026-07-28 | 1295.92% | 158.67% | -$0.10 | $55.91 |
| 2026-07-27 | 1295.92% | 158.67% | -$0.10 | $56.68 |
| 2026-07-26 | 1295.92% | 158.67% | -$0.10 | $57.36 |
| 2026-07-24 | 1295.92% | 158.67% | -$0.10 | $57.36 |
| 2026-07-23 | 1295.92% | 158.67% | -$0.10 | $56.68 |
| 2026-07-22 | 1295.92% | 158.67% | -$0.10 | $56.26 |
Reports Featuring TVTX
Recent News
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...GuruFocus.com
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InInvestor's Business Daily
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Travere Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 9888.53%, based on analyst consensus.
When was the latest EPS estimate revision for TVTX?▾
The most recent revision occurred on 2026-08-06, when analysts adjusted the next-year EPS growth estimate from 4159.03% to 9888.53%.
What sector and industry does Travere Therapeutics Inc belong to?▾
Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.